The ProxiPlate is PerkinElmer's shallow-well microplate, offering closer proximity to the analyzer's detectors. Designed to miniaturize your assay and utilize cost reduction advantages.
Leveraging years of assay and instrument experience in plate detection, PerkinElmer designs better microplates for better performance that guarantees better results for all PerkinElmer applications.
Well format: 384-well
| Description | Specification |
|---|---|
| Number of Rows | 16 |
| Number of Columns | 24 |
| Well volume | 28 µL |
| Recommended working volume | 10 µL- 20 µL |
| Height (mm) | 14.35 |
| Length (mm) | 127.76 |
| Width (mm) | 85.48 |
| Well diameter (mm) | 3.3 |
| Well depth (mm) | 5.3 |
| A1 to top offset (mm) | 8.99 |
| A1 to side offset (mm) | 12.13 |
| Well-to-well spacing (mm) | 4.5 |
| Automation Compatible | Yes |
|---|---|
| Coating Treatment | Untreated |
| Color | White |
| Detection Method | Luminescence, Alpha, Time-Resolved Fluorescence (TRF & TR-FRET), Radiometric |
| Material | Polystyrene |
| Product Brand Name | ProxiPlate |
| Shipping Condition | Ambient |
| Sterile | No |
| Unit Size | Case of 50 |
| Wells Number | 384 well plate |
| Well Shape | Shallow-well |
While fundamental knowledge about tumor immunology has exploded recently, a new therapeutic approach to cancer is taking off: immunotherapy. Instead of directly attacking tumor cells, the idea is to help the immune system recognize and destroy them.
The use of CAR-T cells (Chimeric Antigen Receptor-T Cells), a new avenue of immunotherapy, consists in genetically modifying the patient's immune cells to arm them against a tumor. Concretely, T lymphocytes are taken from the patient's blood and modified in vitro. This leads to their expression of specific surface receptors, which recognize a tumor antigen. Once modified, these CAR-T cells are multiplied and re-injected into the patient's body in large quantities. There they go on to destroy cancer cells after binding to the tumor antigen, releasing a mixture of cytokines and pro-inflammatory chemokines.
This application note focuses on detecting cytokine and chemokine secretion using two orthogonal no-wash immunoassays, AlphaLISA® and HTRF®, in an in vitro co-culture model with CAR-T cells and CD19 positive Raji cells targeting tumors.
